



Principal Pharmaceuticals & Chemicals Ltd.
513, Palm Spring, Link Road, Malad West, Mumbai - 400 064
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2012

PRINCIPAL
Rs. In lacs except EPS

Sr. No.		3 Months ended	3 Months ended	3 Months ended	Year ended
		30th June, 2012	31st March, 2012	30th June, 2011	31st March, 2012
		Un-Audited	Audited	Un-Audited	Audited
1	Net Sales/Income from Operations	4.96	4.97	4.50	19.52
2	Other Income	-	0.13	0.08	0.21
	Total Income	4.96	5.10	4.58	19.73
3	Total Expenditure				
a.	(Increase)/decrease in stock trade	-	-	-	-
b.	Consumption of raw materials / Purchases	-	-	-	-
c.	Staff Cost	1.50	0.38	0.38	1.50
d.	Power & Fuel & Oil	-	-	-	-
e.	Job processing charges	-	-	-	-
f.	Internet Business Development Cost	-	-	-	-
g.	Other expenditure	1.61	3.77	4.23	10.08
4	Interest			-	-
5	Depreciation & Amortisation	2.94	1.56	9.34	10.23
6	Profit/(Loss) before tax (1+2-3-4-5)	(1.09)	(0.61)	(9.37)	(2.08)
	Less :				
7	Provision for taxation				
	- Current Year Tax	-	-	-	-
	- Deferred Tax	-	-	-	-
8	Net Profit /(Loss) (6-7)	(1.09)	(0.61)	(9.37)	(2.08)
	Extraordinary Items				
9	Less : Relisting Fee	-	-	-	(4.80)
10	Balance carried to the balance sheet	(1.09)	(0.61)	(9.37)	(6.88)
11	Paid-up equity share capital	434.96	434.96	599.97	434.96
	(Face value Rs. 10 each upto 30th March 2012. Post Reduction Face Value is reduced to Rs. 4/- each wef 31st March, 2012)				
12	Reserve excluding revaluation reserves (Net of debit balance of Profit & Loss Account)				(336.94)
13	Basic & diluted EPS for the period, for the year to date & for the previous year (prior to extra ordinary item) (not to be annualised)	(0.00)	(0.01)	(0.16)	(0.03)
14	Basic & diluted EPS for the period, for the year to date & for the previous year (after extra ordinary item) (not to be annualised)	(0.00)	(0.01)	(0.16)	(0.11)
15	Aggregate of Non-Promoters' Shareholding				
	No. of shares (in lacs)	40.79	40.79	40.79	40.79
	Percentage of Shareholding	37.51%	37.51%	67.99%	37.51%
16	Promoters and Promoter Group Shareholding				
	a. Pledged /Encumbered				
	- No. of Shares (in lacs)	-	-	-	-
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of Shares (as a % of total sharecapital of the company)	-	-	-	-
	b. Non - Encumbered				
	- No. of Shares (in lacs)	67.95	67.95	19.21	67.95
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (as a % of total sharecapital of the company)	62.49%	62.49%	32.01%	62.49%






PRINCIPAL

- 1 In the Board meeting held on 31st May, 2012, the company decided to expand its business activities into Digital and eCommerce space with immediate effect besides the existing business activities of manufacturing APIs & Intermediates. The new business activities shall be carried out in a new division of the company named '**Inovent Digital**' and shall include, interalia, online selling, digital marketing and e-commerce fulfillment services. No separate segment results are provided for this quarter as the total revenue of the Company is from i.e. Active Pharmaceuticals Intgrediaents (API) & Intermediates.
- 2 The Rehabilitation Scheme (RS) was approved by the Board for Industrial & Financial Reconstruction (BIFR) on 14th July, 2011 and the necessary rectification was approved on 26th March, 2012. The company has taken steps to implementing the RS and accordingly, has reduced its paid up capital by 60% and also issued fresh capital (partly as per the shceme) to the Promoters. Consequent to such reduction and fresh issue of capital, the company's NET WORTH turns positive and technically, the company is now eligible of getting discharged from Hon'ble BIFR. Accordingly, the Monitoring Agency reviewed the same in their meeting held on 18th July, 2012 and thereafter, requested Hon'ble BIFR to discharge the company immediately, as it is now having POSITIVE Net Worth and POSITIVE CASH FLOW for the last few years.
- 3 The listing approval of the reduced capital and fresh capital from Bombay Stock Exchange has been received and trading shall resume after the necessary corporate action by NSDL and CDSL.
- 4 There were no complaints pending at the beginning of 1st Quarter . Complaints received during 1st Quarter - NIL; Complaints solved during 1st Quarter - NIL; Complaints pending at the end of 1st Quarter - NIL.
- 5 The above result has been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 30th July, 2012. The Statutory Auditors have carried out a limited review of the above results as required under clause 41 of the listing agreement with the stock exchange.

Place : Mumbai
Dated : 30th July, 2012

By Order of the Board

Pradeep Malu
President & CEO



pg 2 of 2